Stocks · Healthcare · Biotechnology
Praxis Precision Medicines, Inc. PRAX
$295.51 +3.00% Close, Oct 2, 2026 · NASDAQ · Market cap $8.24B
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 35.7% in a year.
- Over the past year the stock returned +457.4%, ahead of the S&P 500 by 442.3 percentage points.
- The company holds net cash of $473.7M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 43%
- Accruals (lower is better)Bottom 26%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 42%
- Free-cash-flow yieldTop 48%
- EBITDA / enterprise valueTop 50%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 1%
- 6-month returnBottom 37%
- 1-year return vs S&P 500Top 2%
- Distance from 52-week highTop 39%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 45%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 49%
- Upside to consensus price targetTop 36%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 50%
- Maximum drawdown, 3 yearsTop 47%
- Beta vs S&P 500 (lower is better)Bottom 7%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -28.2% | — | Bottom 43% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.4%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -15.07%
- Shareholder yield
- -15.07%
- Share count change, 1 year
- +35.7%
- Share count change, 3-year CAGR
- +84.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +5.8%
- Average 2-day reaction, last 8
- -3.8%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $603.83
- Target vs current price
- +104.3%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 78%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +21.8% | +16.0% | +21.0% | +12.0% | — |
| May 7, 2026 | +10.6% | -1.4% | +2.6% | -21.7% | -9.6% |
| Feb 19, 2026 | -12.0% | +0.8% | +5.7% | -12.2% | +5.0% |
| Nov 5, 2025 | +2.6% | -4.1% | +6.9% | +8.4% | +80.0% |
| Aug 4, 2025 | +2.6% | -5.5% | -15.1% | -15.8% | +243.8% |
| May 2, 2025 | -2.8% | +5.7% | +0.0% | +1.3% | +47.0% |
| Feb 28, 2025 | -6.5% | -40.6% | -41.8% | -40.3% | -42.3% |
| Nov 6, 2024 | -36.8% | -1.2% | +14.1% | +2.0% | +14.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$2.87 | -$3.67 | +21.8% | — |
| May 7, 2026 | -$3.20 | -$3.58 | +10.6% | — |
| Feb 19, 2026 | -$3.50 | -$3.13 | -12.0% | — |
| Nov 5, 2025 | -$3.36 | -$3.45 | +2.6% | — |
| Aug 4, 2025 | -$3.31 | -$3.40 | +2.6% | — |
| May 2, 2025 | -$3.29 | -$3.20 | -2.8% | — |
| Feb 28, 2025 | -$2.94 | -$2.76 | -6.5% | $7.5M |
| Nov 6, 2024 | -$2.75 | -$2.01 | -36.8% | $302,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -3.71% | — | — | Top 48% |
| Earnings yield | -4.38% | — | — | Top 42% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -1.6%
- 200-day average slope (20 days)
- +3.1%
- Distance from 50-day average
- -11.3%
- Distance from 200-day average
- -6.7%
- RSI (14)
- 40.5
- Relative volume
- 1.02×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 55.7%
- Volatility vs own 5-year history
- 6th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.32
- Correlation with S&P 500
- 0.18
- Current drawdown from 1-year high
- -23.5%
- Maximum drawdown, 3 years
- -68.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 7, 2021 | Mar 30, 2023 | -98.7% | 560 days | Not yet recovered |
| Nov 9, 2020 | Nov 10, 2020 | -21.8% | 1 days | 11 days (Nov 25, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $8.24B
- EPS, diluted (TTM)
- -$12.93
- Revenue (TTM)
- $0
- 52-week range
- $50.31 – $392.70
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.4M | $8.6M | $0 |
| Gross profit | $0 | -$154.4M | -$84.3M | -$143.9M | -$140,000 |
| Operating income | -$167.3M | -$215.0M | -$126.4M | -$200.2M | -$326.2M |
| Net income | -$167.1M | -$214.0M | -$123.3M | -$182.8M | -$303.3M |
| EPS (diluted) | -$58.96 | -$69.33 | -$18.69 | -$10.21 | -$13.48 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $302,000 | $7.5M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$51.9M | -$58.7M | -$69.3M | -$71.1M | -$73.9M | -$88.9M | -$92.6M | -$83.7M |
| EPS (diluted) | -$2.75 | -$2.94 | -$3.29 | -$3.31 | -$3.36 | -$3.50 | -$3.20 | -$2.87 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$124.6M | -$185.0M | -$111.1M | -$131.8M | -$249.1M |
| Capital expenditure | -$1.1M | -$444,000 | -$50,000 | $0 | -$56,000 |
| Free cash flow | -$125.6M | -$185.5M | -$111.2M | -$131.8M | -$249.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $105.7M | $9.6M | $91.6M | $512.0M | $704.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $758.6M
- Total assets
- $1.39B
- Total liabilities
- $49.1M
- Total debt
- $1.1M
- Net debt
- -$473.7M
- Shareholders’ equity
- $1.34B
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 3,795,697
- Days to cover
- 14.88
- Change vs previous report
- +1.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Nov 29, 2023
- 1-for-15